NEW YORK, Oct. 22, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Extra value: One year of free online updates included with this product
There are today at least 303 targeted molecular therapies known to affect more than 250 specific intracellular signaling pathways for the treatment of ovarian cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 225 drug targets that are included in this drug-pathway analyzing tool. No less than 222 of these have been recorded with mutations and 43 drug targets have mutations which have been causally implicated in cancer.
- BioCarta# 235 Pathways
- KEGG# 169 Pathways
- NCI-Nature# 250 Pathways
- NetPath# 32 Pathways
Phase III# 20
Phase II# 104
Phase I# 97
No Data# 4
The continuous identification of drug targets and pathways that are altered in cancer is not only crucial for our understanding of cancer biology, but also to search for new targets for early diagnosis and improved treatment designs. Consequently, it has never before been as important to rapidly translate systems biology of disease and therapeutics to actionable pipeline decisions to ensure that the optimal market conditions exist by the time a candidate drug is commercialized.
For this reason BioSeeker, a leader in pipeline analytics, has constructed this high-level drug-pathway analyzer which lets you interact with the ovarian cancer pipeline in a whole different than way than you ever done before. Its capabilities moves you beyond powerful competitive intelligence to an opportunity seeking tool which lets you, by means of both present and emerging scientific knowledge, analyze the ovarian cancer pipeline for interesting compounds which affect and/or fit your purposes, may it be benchmarking, in/out-licensing, combination therapy options, drug repositioning, indication expansion etc.
You Use this Analyzer Tool in ovarian cancer to:
* Map the competition and find suitable benchmarking/licensing drugs based on specific pathways and drug properties
* Uncover potential indication expansion areas for your drug portfolio
* Reveal repositioning opportunities for your older, shelved drugs
* Evaluate the progression and success of targeting certain pathways by different tumor types
* Investigate drugs which affect crosstalk between key pathways
* Investigate different combination therapy options available to you in various cancer types. Use this tool to look for the most-efficient ways to combine your drug with other targeted agents.
* Find possible adjuvant therapy settings with other drugs.
This is how you do it:
In analyzing drug-pathway relationships this tool has three core modes:
1. Select - You go right ahead and select any pathway for analysis
2. Suggest - The tool can suggest pathways to you according to your pipeline specifications
3. Compare - You can overlay any pathways with each other and do a comparative analysis
You can interactively analyze any ovarian cancer drug-pathway relationship by using up to four different pathway sources and further refine your analysis with up to 20 different pipeline parameters, including parameters such as presence of mutations, molecular function of targets, stage of development, sub-cellular localization and many more. Each parameter has multi-select options to them and can be used as either an inclusion parameter or exclusion parameter.
User Reports with Graphics
Each analysis report generated in the Drug Pathway Analyzer includes many different types of graphs and tables which can also be easily downloaded and dropped into applications such as PowerPoint for external presentations outside the tool.
The Pathway Analyzer Comes Integrated with Pipeline Information
With a simple click you can easily and quickly get relevant information about the drug being included in a specific pathway. A typical drug profile reports on, depending on stage of development and available information:
Drug Name & Synonyms
Presentation of drug name and synonyms
Principal Company & Partners
Presentation of principal company and partners
Target and Molecular Function of Target
Described target(s) is/are presented with:
Official Gene Symbol – Chromosome Location – Gene & Protein Name – Molecular Function
Described target(s) is/are presented with primary and alternate localizations.
Target Expression Profiles
Links to protein expression profile(s) of target(s) in various human tissues, cell lines and primary cells, including up to:
48 different normal tissue types
20 different types of cancer
47 cell lines
12 samples of primary blood cells
All targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers.
The identity of available biological structures on drug targets was retrieved from the RCSB Protein Databank for you to easily review what available structures of drug targets exist.
Described target(s) is/are matched for the involvement in cellular pathways according to BioCarta, KEGG, NCI-Nature and NetPath.
Drug mechanism of action
Summary field of developmental projects for the drug, including indication, developmental stage and status.
Cancer, myeloma – Phase II Clinical Trial – Active
Cancer, prostate – Phase III Clinical Trial – Ceased
Short introduction to drug
Compound type, Chemical name, CAS Number and molecular weight
Available patent information related to the drug is presented here.
Fillings and Approvals
Approvals and submissions
Deals & Licensing
Collaborations and deals
Availability for licensing
Phase IV Data
Available Phase IV development data, developmental history and scientific data.
Phase III Data
Available Phase III development data, developmental history and scientific data.
Phase II Data
Available Phase II development data, developmental history and scientific data.
Phase I Data
Available Phase I development data, developmental history and scientific data.
Phase 0 Data
Available Phase 0 development data, developmental history and scientific data.
Available preclinical development data, developmental history and scientific data.
Available discovery development data, developmental history and scientific data.
- Operating system: Windows (2000/XP/Vista/7/8) and Mac Users are offered Online Access Only
- Browser Application (Internet Explorer)
- Internet access (to access related internet resources)
To order this report: Ovarian Cancer Drug Pathway Analyzer 2013
Contact Clare: email@example.com
Intl: +1 339-368-6001